Astrid Lièvre
Inserm(FR)Université Rennes 2(FR)Oncogenesis Stress Signaling(FR)Centre Hospitalier Universitaire de Rennes(FR)Université de Rennes(FR)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Colorectal and Anal Carcinomas, Genetic factors in colorectal cancer, Gastric Cancer Management and Outcomes, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer(2006)2,215 cited
- → Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer(2021)1,676 cited
- → KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab(2008)1,450 cited
- → Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer(2009)665 cited
- → Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study(2022)357 cited
- → Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers